Business highlights in October-December 2024
- The Company completed the capital increase of 108,500 shares directed to members of executive management and key management under the LTI2023 incentive program, as well as the share-buy back of 23,000 treasury shares and subsequent re-sale of those shares to board members under the same incentive program
Business highlights after this reporting period
- Nothing to report
Financial Highlights
| Fourth Quarter (2024-10-01 – 2024-12-31) |
| Net revenue were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -2,701 (-4,279) |
| Earnings per share before and after dilution was DKK -0.02 (0.03) |
| Cash: TDKK 13,371 (24,336) |
| Solidity: 97% (37%) |
| Full Year (2024-01-01 – 2024-12-31) |
| Net revenues were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -14,502 (-27,029) |
| Earnings per share before and after dilution was DKK –0.23 (-0.44) |
Solidity: equity divided by assets.
The Board of Directors have decided that interim reports will be published in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/